Pathological complete response to radical surgery after receiving durvalumab plus neoadjuvant chemotherapy for 1 limited-stage small cell lung cancer patient: a case report

BACKGROUND: Small cell lung cancer (SCLC) is clinically the most aggressive subtype of lung cancer, and accounts for about 15% of all newly diagnosed lung cancer cases. Approximately 1/3 of SCLC patients are diagnosed with limited-stage SCLC (LS-SCLC). The standard of treatment for most patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhifeng, Zhang, Boyi, Yang, Fuyao, Yang, Liwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091040/
https://www.ncbi.nlm.nih.gov/pubmed/35571672
http://dx.doi.org/10.21037/tcr-22-729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091040/
https://www.ncbi.nlm.nih.gov/pubmed/35571672
http://dx.doi.org/10.21037/tcr-22-729

Ejemplares similares